How early is early: Androgen deprivation for prostate-specific antigen relapse in prostate cancer [1]

Journal of Clinical Oncology

Volumn 24, Issue 18, 2006, Pages 2964-

  Duchesne, Gillian M ^a   Syme, Rodney ^a   Howell, Deborah ^a  

^a CANCER EPIDEMIOLOGY CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

CANCER RELAPSE; CANCER STAGING; DECISION MAKING; DISEASE COURSE; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; TREATMENT FAILURE; BLOOD; MALE; NOTE; PROSTATE TUMOR; TIME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 33745548123     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.8420     Document Type: Letter

References (9)

1. Ryan CJ, Small EJ: Early versus delayed androgen deprivation for prostate cancer: New fuel for an old debate. J Clin Oncol 23:8225-8231, 2005
2. The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br. J Urol 79:235-246, 1997
3. Studer UE, Hauri D, Hanselmann S, et al: Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: Results of the randomized trial SAKK 08/88. J Clin Oncol 22:4109-4118, 2004
4. Kirk D, on behalf of the MRC Prostate Cancer Working Party Investigators Group: Immediate vs deferred hormone treatment for prostate cancer: How safe is androgen deprivation? Br J Urol Int 86:220, 2000 (suppl 3)
5. Bianco FJ, Dotan ZA, Kattan MW, et al: Duration of response to androgen deprivation therapy and survival after subsequent biochemical relapse in men initially treated with radical prostatectomy. J Clin Oncol 22: 394s, 2004 (abstr 4552)
6. Wallace KL, Elkin EP, Latini DM, et al: Timing of LHRH treatment after PSA failure in prostate cancer patients: A survival analysis from the CAPSURE database. Proc Am Urol Assoc, 2004 (abstr 434)
7. Duchesne GM, Millar JL, Moraga V, et al: What to do for prostate cancer patients with a rising PSA? - A survey of Australian practice. Int J Radiat Oncol Biol Phys 55:986-991, 2003
8. Salminen EK, Wickstrom JE, Vahlberg T, et al: Trends in the use of androgen deprivation in prostate cancer. Acta Oncol 43:382-387, 2004
9. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999